Challenges and advances in CAR-T cell therapy for B-ALL
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment landscape for hematological malignancies such as relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with several CAR-T products now approved globally for R/R B-ALL. Despite high initial respo...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2026-05-01
|
| Seri Bilgileri: | Biomarker Research |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s40364-026-00933-z |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|